Roche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics

Monday, June 8, 2026Robert BarrieView original

Roche believes its new BTK-degrader bexobrutideg will outperform approved BTK-inhibitors in B-cell malignancies.

Read the full article on the original site.